04.08.15
Richmond, Calif.-based Ekso Bionics Holdings Inc. has added Amy Wendell, former senior vice president, strategy and business development of Covidien, global health care products company and manufacturer of medical devices and supplies, to its board of directors.
“At Covidien, Amy Wendell presided over an impressive acquisition strategy, acquiring more than 100 companies with leading edge technologies across many healthcare sectors. She has combed through an incredible number of growth strategies and understands the ones that really make sense,” said Nathan Harding, CEO and co-founder. “We look forward to benefiting from Amy’s operational and product management experience as well as her strategic acumen.”
“We were dedicated to finding a board member with all of the attributes that Amy Wendell embodies for over a year now and we are proud to welcome such an exceptional individual,” said Steven Sherman, Ekso Bionics’ chairman. “I am confident that Amy is going to make a significant and positive impact on our company.”
“I have a long time interest in medical device technology and, perhaps even more, the process of guiding innovative companies to make a positive impact in people’s lives, hit business milestones and expand into new markets,” said Amy Wendell, a 29-year veteran at Covidien. “I am excited by what Ekso Bionics has begun to accomplish and I am honored to be joining their board.”
Since 1986, Amy Wendell has served in a range of leadership positions at Covidien, formerly known as Tyco Healthcare/Kendall, where she led the company’s strategic planning and portfolio management functions, as well as all business development initiatives including mergers and acquisitions, integrations, equity investments, divestitures, licensing, distribution, and market intelligence. Amy received a bachelor’s degree from Lawrence Institute of Technology (Mich.) and a master’s degree in biomedical engineering from the University of Illinois.
Wendell’s appointment increases the size of Ekso Bionics’ board of directors to seven.
Ekso Bionics makes robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility.
“At Covidien, Amy Wendell presided over an impressive acquisition strategy, acquiring more than 100 companies with leading edge technologies across many healthcare sectors. She has combed through an incredible number of growth strategies and understands the ones that really make sense,” said Nathan Harding, CEO and co-founder. “We look forward to benefiting from Amy’s operational and product management experience as well as her strategic acumen.”
“We were dedicated to finding a board member with all of the attributes that Amy Wendell embodies for over a year now and we are proud to welcome such an exceptional individual,” said Steven Sherman, Ekso Bionics’ chairman. “I am confident that Amy is going to make a significant and positive impact on our company.”
“I have a long time interest in medical device technology and, perhaps even more, the process of guiding innovative companies to make a positive impact in people’s lives, hit business milestones and expand into new markets,” said Amy Wendell, a 29-year veteran at Covidien. “I am excited by what Ekso Bionics has begun to accomplish and I am honored to be joining their board.”
Since 1986, Amy Wendell has served in a range of leadership positions at Covidien, formerly known as Tyco Healthcare/Kendall, where she led the company’s strategic planning and portfolio management functions, as well as all business development initiatives including mergers and acquisitions, integrations, equity investments, divestitures, licensing, distribution, and market intelligence. Amy received a bachelor’s degree from Lawrence Institute of Technology (Mich.) and a master’s degree in biomedical engineering from the University of Illinois.
Wendell’s appointment increases the size of Ekso Bionics’ board of directors to seven.
Ekso Bionics makes robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility.